ATE136782T1 - Feste zubereitung von aktivem vitamin d3 mit verbesserter stabilität - Google Patents
Feste zubereitung von aktivem vitamin d3 mit verbesserter stabilitätInfo
- Publication number
- ATE136782T1 ATE136782T1 AT90903930T AT90903930T ATE136782T1 AT E136782 T1 ATE136782 T1 AT E136782T1 AT 90903930 T AT90903930 T AT 90903930T AT 90903930 T AT90903930 T AT 90903930T AT E136782 T1 ATE136782 T1 AT E136782T1
- Authority
- AT
- Austria
- Prior art keywords
- solid preparation
- improved stability
- active vitamin
- activated
- vitamin
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 title abstract 2
- 239000000395 magnesium oxide Substances 0.000 abstract 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1046571A JP2525478B2 (ja) | 1989-03-01 | 1989-03-01 | 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE136782T1 true ATE136782T1 (de) | 1996-05-15 |
Family
ID=12751003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90903930T ATE136782T1 (de) | 1989-03-01 | 1990-02-28 | Feste zubereitung von aktivem vitamin d3 mit verbesserter stabilität |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5158944A (de) |
| EP (1) | EP0413828B1 (de) |
| JP (1) | JP2525478B2 (de) |
| KR (2) | KR920700036A (de) |
| AT (1) | ATE136782T1 (de) |
| CA (1) | CA2027592C (de) |
| DE (1) | DE69026555T2 (de) |
| DK (1) | DK0413828T3 (de) |
| ES (1) | ES2085905T3 (de) |
| WO (1) | WO1990009796A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02240024A (ja) * | 1989-03-13 | 1990-09-25 | Ss Pharmaceut Co Ltd | 活性型ビタミンｄ↓３類製剤用組成物 |
| JP2845342B2 (ja) * | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | ビタミンｄ▲下３▼誘導体含有固形製剤組成物 |
| CA2061520C (en) * | 1991-03-27 | 2003-04-22 | Lawrence J. Daher | Delivery system for enhanced onset and increased potency |
| DK0508756T3 (da) * | 1991-04-09 | 1997-03-24 | Takeda Chemical Industries Ltd | Stabiliseret vitamin D-præparat |
| AU661080B2 (en) * | 1991-11-22 | 1995-07-13 | Warner Chilcott Company, Llc | Risedronate delayed-release compositions |
| US6096342A (en) | 1997-03-12 | 2000-08-01 | The Procter & Gamble Company | Dosage forms of risedronate |
| WO1993012082A1 (fr) * | 1991-12-11 | 1993-06-24 | Central Glass Co., Ltd. | Derive de 24,25-dihydroxyvitamine d¿3? |
| IL103224A (en) * | 1992-09-18 | 1998-08-16 | Teva Pharma | Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
| US6406714B1 (en) | 1992-12-02 | 2002-06-18 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids |
| US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| US6103709A (en) * | 1993-12-23 | 2000-08-15 | The Regents Of The University Of California | Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs and methods for treatment of vitamin D diseases |
| FR2724844B1 (fr) * | 1994-09-23 | 1997-01-24 | Innothera Lab Sa | Association therapeutique vitamino-calcique, son procede d'obtention et son utilisation |
| US6716454B2 (en) | 1994-09-23 | 2004-04-06 | Laboratorie Innothera, Société Anonyme | Therapeutic combination of vitamin and calcium in unitary galenic tablet form, a method of obtaining it, and the use thereof |
| US5698222A (en) * | 1995-04-07 | 1997-12-16 | Abbott Laboratories | Calcium supplement |
| US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| US6395770B1 (en) | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
| AT408416B (de) * | 1996-07-19 | 2001-11-26 | Norbert Fuchs | Pharmazeutische bzw. diätetische zusammensetzungen |
| FI120290B (fi) * | 1996-12-30 | 2009-09-15 | Mirador Res Oy Ltd | Menetelmä, jonka avulla voidaan valmistaa sellaisia mausteseos-, ruoan ainesosa- ja elintarvikekoostumuksia, jotka alentavat seerumin kolesterolia |
| DE19710054A1 (de) * | 1997-03-12 | 1998-09-17 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| AR024462A1 (es) | 1999-07-01 | 2002-10-02 | Merck & Co Inc | Tabletas farmaceuticas |
| KR100611544B1 (ko) * | 2000-08-30 | 2006-08-10 | 쥬가이 세이야쿠 가부시키가이샤 | 오씨티 제제 |
| KR100688618B1 (ko) * | 2001-09-12 | 2007-03-09 | 주식회사 유유 | 비타민 ｄ 경구투여용 서방성 약제 조성물 |
| MXPA04005260A (es) * | 2001-12-03 | 2005-03-23 | Novacea Inc | Composiciones farmaceuticas que comprenden compuestos activos de vitamina d. |
| US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| US20040058895A1 (en) * | 2002-09-18 | 2004-03-25 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
| US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
| US20060189586A1 (en) * | 2003-06-11 | 2006-08-24 | Cleland Jeffrey L | Pharmaceutical compositions comprising active vitamin D compounds |
| CA2882048C (en) | 2006-02-03 | 2020-03-24 | Opko Renal, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| HUE037309T2 (hu) | 2006-06-21 | 2018-08-28 | Opko Ireland Global Holdings Ltd | Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer |
| WO2009047644A2 (en) | 2007-04-25 | 2009-04-16 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
| ES2401205T3 (es) | 2007-04-25 | 2013-04-17 | Cytochroma Inc. | Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo |
| CA2713765A1 (en) * | 2008-02-06 | 2009-08-13 | Innov'ia | Pulverulent composition and a process for preparing the same |
| CN103037902A (zh) | 2010-03-29 | 2013-04-10 | 赛特克罗公司 | 用于降低甲状旁腺水平的方法和组合物 |
| EP2468265A3 (de) * | 2010-12-04 | 2013-01-02 | DEEF Pharmaceutical Industries Co. | Homogene Zubereitungen mit Vitamin D |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| JP7034595B2 (ja) * | 2016-03-23 | 2022-03-14 | 株式会社ファンケル | ビタミンｄ３安定化組成物 |
| EP4596045A3 (de) | 2016-03-28 | 2025-10-15 | EirGen Pharma Ltd. | Verfahren zur behandlung von vitamin d |
| WO2018124260A1 (ja) * | 2016-12-28 | 2018-07-05 | 中外製薬株式会社 | Ｅｄ－７１の固体分散体および油分分散体を含む医薬組成物 |
| US11638439B2 (en) * | 2018-05-21 | 2023-05-02 | Agthia | Vitamin D-fortified water and method of manufacturing thereof |
| KR102708351B1 (ko) | 2018-06-27 | 2024-09-20 | 추가이 세이야쿠 가부시키가이샤 | 유지 중에 ed-71 및 그의 에폭시체를 포함하는 유분 분산체를 포함하는 의약 조성물 |
| CN119236100B (zh) * | 2023-06-25 | 2025-08-19 | 广州朗圣药业有限公司 | 一种维生素d3包合物及其制剂、制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2195596A (en) * | 1936-11-07 | 1940-04-02 | Squibb & Sons Inc | Protected-vitamin-containing tablet |
| US2691619A (en) * | 1951-09-18 | 1954-10-12 | Pfizer & Co C | Fat-soluble vitamin-containing products and process therefor |
| DE1492034A1 (de) * | 1965-05-18 | 1969-02-20 | Merck Ag E | Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln |
| US3901928A (en) * | 1973-01-10 | 1975-08-26 | Robert Henry Hesse | 1' ,3' -dihydroxy steroid-5-enes method of preparing same and their use for preparing 1' -hydroxy-25-hydrogen vitamin d compounds |
| JPS5418330B2 (de) * | 1973-03-16 | 1979-07-06 | ||
| DE2400819C2 (de) * | 1974-01-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung |
| JPS51128417A (en) * | 1975-04-28 | 1976-11-09 | Teijin Ltd | A method for stabilizing active vitamin d3 derivatives |
| US4069321A (en) * | 1975-10-14 | 1978-01-17 | Merck & Co., Inc. | Blocked cholecalciferol and dihydrotachysterol 3 derivatives |
| JPS5740414A (en) * | 1980-08-25 | 1982-03-06 | Teijin Ltd | Novel active type vitamin d3 derivative composition |
| JPS5740461A (en) * | 1980-08-25 | 1982-03-06 | Teijin Ltd | Novel activated vitamin d3 derivative composition |
| JPS5740415A (en) * | 1980-08-25 | 1982-03-06 | Teijin Ltd | Novel active type vitamin d3 derivative composition |
| US4308264A (en) * | 1981-01-28 | 1981-12-29 | Abbott Laboratories | Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration |
| US4652405A (en) * | 1981-08-28 | 1987-03-24 | Hoffman-La Roche Inc. | Synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol |
| US4617297A (en) * | 1982-02-12 | 1986-10-14 | Hoffmann-La Roche Inc. | Method of treating disease states by the administration of 1α,25,26-trihydroxycholecalciferol |
| JPS58206533A (ja) * | 1982-05-27 | 1983-12-01 | Teijin Ltd | 活性型ビタミンｄ↓３誘導体組成物及びそれを活性成分とする薬剤 |
| JPS59155309A (ja) * | 1983-02-22 | 1984-09-04 | Teijin Ltd | 活性型ビタミンｄ↓３類組成物 |
| JPS6141351A (ja) * | 1984-07-31 | 1986-02-27 | 日産自動車株式会社 | 空気噴射式織機の緯糸端部処理装置 |
| JPS6144860A (ja) * | 1984-08-10 | 1986-03-04 | Taisho Pharmaceut Co Ltd | １α．２５−ジヒドロキシ−２６．２７−ジメチルビタミンＤ↓３ |
| US4613594A (en) * | 1984-11-16 | 1986-09-23 | Hoffmann-La Roche Inc. | Fluorinated vitamin D3 compounds |
| JPS6217A (ja) * | 1985-02-14 | 1987-01-06 | Chugai Pharmaceut Co Ltd | 安定な活性型ビタミンｄ３類製剤 |
| JPS6251948A (ja) * | 1985-07-23 | 1987-03-06 | 廖 阿亮 | デコレーション用プレザープとその製造方法 |
| JPH0635442B2 (ja) * | 1985-08-28 | 1994-05-11 | 住友精化株式会社 | チオカルバメ−ト誘導体の製造法 |
| JPS62149619A (ja) * | 1985-09-05 | 1987-07-03 | Teijin Ltd | 活性型ビタミンｄ３類注射用組成物 |
| JPS6346728A (ja) * | 1986-08-15 | 1988-02-27 | Hitachi Electronics Eng Co Ltd | ランプ電源制御方式および制御回路 |
| JPS6425723A (en) * | 1988-07-07 | 1989-01-27 | Teijin Ltd | Production of active type vitamin d3 composition |
-
1989
- 1989-03-01 JP JP1046571A patent/JP2525478B2/ja not_active Expired - Fee Related
-
1990
- 1990-02-28 DE DE69026555T patent/DE69026555T2/de not_active Expired - Fee Related
- 1990-02-28 KR KR1019900702365A patent/KR920700036A/ko active Granted
- 1990-02-28 EP EP90903930A patent/EP0413828B1/de not_active Expired - Lifetime
- 1990-02-28 DK DK90903930.7T patent/DK0413828T3/da active
- 1990-02-28 AT AT90903930T patent/ATE136782T1/de not_active IP Right Cessation
- 1990-02-28 US US07/601,775 patent/US5158944A/en not_active Expired - Lifetime
- 1990-02-28 ES ES90903930T patent/ES2085905T3/es not_active Expired - Lifetime
- 1990-02-28 CA CA002027592A patent/CA2027592C/en not_active Expired - Fee Related
- 1990-02-28 KR KR1019900702365A patent/KR930010621B1/ko not_active Expired - Lifetime
- 1990-02-28 WO PCT/JP1990/000255 patent/WO1990009796A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0413828B1 (de) | 1996-04-17 |
| JP2525478B2 (ja) | 1996-08-21 |
| ES2085905T3 (es) | 1996-06-16 |
| DE69026555T2 (de) | 1996-09-19 |
| JPH02229115A (ja) | 1990-09-11 |
| DK0413828T3 (da) | 1996-05-13 |
| DE69026555D1 (de) | 1996-05-23 |
| KR920700036A (ko) | 1992-02-19 |
| CA2027592C (en) | 1996-11-26 |
| CA2027592A1 (en) | 1990-09-02 |
| EP0413828A4 (en) | 1991-10-30 |
| EP0413828A1 (de) | 1991-02-27 |
| WO1990009796A1 (en) | 1990-09-07 |
| US5158944A (en) | 1992-10-27 |
| KR930010621B1 (ko) | 1993-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69026555D1 (de) | Feste zubereitung von aktivem vitamin d3 mit verbesserter stabilität | |
| DZ1067A1 (fr) | Nouvelles préparations pharmaceutiques à emission prolongée. | |
| DK0645145T3 (da) | Stabiliseret farmaceutisk præparat og stabiliseringsopløsningsmiddel | |
| ATE156355T1 (de) | Stabile zusammensetzungen von askorbinsäure | |
| FR2634376B1 (fr) | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation | |
| FI863652A0 (fi) | 7-isopropoxiisflavoninklusionskomplex bildat med cyklodextrin och ett foerfarande foer dess framstaellning. | |
| KR880004811A (ko) | 산화에 안정한 약제 조성물 | |
| LV10270A (lv) | 2-[(2-Piridinil)metilsulfinil-(vai sulfonil)]-1H-benzimidazol-1-ila atvasinajumi to iegusanas panemiens farmaceitiska kompozicija uz to bazes pielietojums | |
| DE3875425D1 (de) | Vasokinetisch wirkende polyungesaettigte saeuren und sie enthaltende pharmazeutische oder kosmetische zubereitungen. | |
| DE3875837D1 (de) | Pharmazeutische und kosmetische mittel, die komplexe von flavanolignanen mit phospholipeden enthalten. | |
| DK395689D0 (da) | Pharmaceutisk tilberedning til behandling af diabetes mellitus | |
| ES2094290T3 (es) | Preparacion estabilizada de vitamina d. | |
| IT1187750B (it) | Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute | |
| KR840005024A (ko) | 제약혼합물제제 및 그 제조방법 | |
| FI940696A0 (fi) | Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö | |
| ATA186692A (de) | Pharmazeutische zusammensetzung | |
| ATE98868T1 (de) | Topisch kosmetisch anzuwendende depolymerisierte nukleinsaeuren enthaltende arzneizubereitungen. | |
| KR930001903A (ko) | 유비데카레논 경구용 수용액 제제 | |
| GB2021409A (en) | Pharmaceutical composition | |
| AU629445B2 (en) | Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol | |
| KR930012023A (ko) | 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법 | |
| ATE2746T1 (de) | Piperidinderivate von 4,5-dialkyl-3-hydroxypyrrol-2-carbons[ureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen. | |
| KR870700024A (ko) | 약, 비타민 또는 왁진의 근육내 주사용 제제 | |
| FR2657010B1 (fr) | Composition pharmaceutique sous forme de suspension aqueuse stable a base de sucrafalte et d'une substance anti-acide ainsi que son procede de preparation. | |
| SE8403110L (sv) | Stabiliserad antralinkomposition och sett att stabilisera antralin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |